economybharat.com

We Can Cover You
Click here
Facebook Youtube Instagram Linkedin
13
13

Study

Promising results from AcuCort’s Phase IV study – scientific articles under preparation for international publication

Promising results from AcuCort’s Phase IV study – scientific articles under preparation for international publication

creativebharatgroup@gmail.com January 27, 2025
In mid-November 2024, the final patient completed AcuCort’s Phase IV clinical trial. Subsequently,...
Read More Read more about Promising results from AcuCort’s Phase IV study – scientific articles under preparation for international publication
Consumer prices could rise 3-fold in poor nations by 2050, even under ambitious climate policies: Study, ET Retail 116935078.cms

Consumer prices could rise 3-fold in poor nations by 2050, even under ambitious climate policies: Study, ET Retail

creativebharatgroup@gmail.com January 4, 2025
Even under ambitious climate policies, lower-income countries would see consumer food prices rise 2.45 times by 2050...
Read More Read more about Consumer prices could rise 3-fold in poor nations by 2050, even under ambitious climate policies: Study, ET Retail
Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome

Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome

creativebharatgroup@gmail.com December 17, 2024
Lund, Sweden, 17 December 2024. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), today...
Read More Read more about Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome
Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU

Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU

creativebharatgroup@gmail.com December 10, 2024
Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) did not meet...
Read More Read more about Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU